Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib food-effect dosing study in ALK-positive metastatic non-small cell lung cancer
NL-OMON43595Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ceritinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Novartis. Primary endpoint: Steady-state pharmacokinetic parameters. Started Nov 2015; status: active, not recruiting.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON43595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43595.